{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-273985","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.606497+00:00","generated_at":"2026-05-29T05:14:29.483411+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025","bullets":["Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).","2 of 26 (8%) treatment-arm patients relapsed vs 4 of 12 (33%) controls; median time to relapse not evaluable vs 160 days.","No TP53-mutated patients relapsed in treatment arm (0/4 infused), while both control-arm TP53 patients relapsed within 6 months and died.","Registrational trial for TSC-101 planned for H2 2025 with RFS primary endpoint, powered at HR 0.60, 85% power, ~140 treatment subjects.","Solid tumor program: 8 patients infused singleplex; first T-Plex product manufactured; IND for MAGE-A4 TCR submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-273985","json":"https://secwatch.observer/filing/0001193125-24-273985.json","markdown":"https://secwatch.observer/filing/0001193125-24-273985.md","text":"https://secwatch.observer/filing/0001193125-24-273985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/0001193125-24-273985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/d917413d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:14:29.483411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}